|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
GB8918616D0
(en)
|
1989-08-15 |
1989-09-27 |
Univ Glasgow |
Herpes simplex virus type 1 mutant
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
GB9415319D0
(en)
|
1994-07-29 |
1994-09-21 |
Medical Res Council |
HSV viral vector
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
AU8605598A
(en)
|
1997-07-31 |
1999-02-22 |
University Of Pittsburgh |
Targeted hsv vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
|
NZ522840A
(en)
|
2000-06-01 |
2004-12-24 |
Univ North Carolina |
A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
|
|
ATE452972T1
(de)
|
2001-05-01 |
2010-01-15 |
Ca Nat Research Council |
Induzierbares expressionssystem in eukaryotischen zellen
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
AU2003210149B2
(en)
|
2002-01-03 |
2008-10-09 |
Bayer Schering Pharma Aktiengesellschaft |
Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
DK1765860T3
(da)
|
2004-05-19 |
2009-03-09 |
Immunocore Ltd |
Ny-ESO-T.cellereceptor med höj affinitet
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
EP1934259A2
(en)
|
2005-10-11 |
2008-06-25 |
Ablynx N.V. |
Nanobodies and polypeptides against egfr and igf-ir
|
|
CA2651174A1
(en)
|
2006-05-03 |
2007-11-15 |
Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services |
Chimeric t cell receptors and related materials and methods of use
|
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
EP2406284B9
(en)
|
2009-03-10 |
2017-03-01 |
Biogen MA Inc. |
Anti-bcma antibodies
|
|
ES2683695T3
(es)
|
2010-01-12 |
2018-09-27 |
The University Of North Carolina At Chapel Hill |
Repeticiones terminales invertidas restrictivas para vectores virales
|
|
CA2788682C
(en)
|
2010-02-05 |
2019-03-05 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
CN107164330A
(zh)
|
2011-04-08 |
2017-09-15 |
贝勒医学院 |
使用嵌合细胞因子受体逆转肿瘤微环境的影响
|
|
JP6205363B2
(ja)
|
2011-09-26 |
2017-09-27 |
ジェイエヌ バイオサイエンシーズ エルエルシー |
ハイブリッド定常領域
|
|
US20150218280A1
(en)
|
2012-08-10 |
2015-08-06 |
University Of Southern California |
CD20 scFv-ELPs METHODS AND THERAPEUTICS
|
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
|
WO2014146672A1
(en)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
CA2909701C
(en)
|
2013-04-17 |
2022-12-06 |
Baylor College Of Medicine |
Immunosuppressive tgf-.beta. signal converter
|
|
CN110511960B
(zh)
|
2013-07-15 |
2023-05-23 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
CN107074970B
(zh)
|
2014-08-04 |
2021-07-30 |
弗雷德哈钦森癌症研究中心 |
特异性针对wt-1的t细胞免疫疗法
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
KR20250067191A
(ko)
*
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
JP6865688B2
(ja)
|
2015-01-16 |
2021-04-28 |
ジュノー セラピューティクス インコーポレイテッド |
Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
|
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3842072A1
(en)
|
2015-05-18 |
2021-06-30 |
Eureka Therapeutics, Inc. |
Anti-ror1 antibodies
|
|
EP3331913A1
(en)
*
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
JP2019525898A
(ja)
|
2016-06-10 |
2019-09-12 |
ガデタ・ベー・フェー |
ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
|
|
EP4282877A3
(en)
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
SG11201903400WA
(en)
|
2016-10-17 |
2019-05-30 |
Pfizer |
Anti-edb antibodies and antibody-drug conjugates
|
|
IL266628B2
(en)
|
2016-11-17 |
2024-06-01 |
Bluebird Bio Inc |
TGFBeta signal converter
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
CN110582509A
(zh)
*
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
US11236145B2
(en)
|
2017-03-23 |
2022-02-01 |
Immatics Biotechnologies Gmbh |
T cell receptors and immune therapy using the same against PRAME positive cancers
|
|
WO2018183888A2
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
|
AU2018289428B2
(en)
|
2017-06-21 |
2024-06-27 |
The General Hospital Corporation |
Methods and compositions for chimeric antigen receptor targeting cancer cells
|
|
CA3080274A1
(en)
|
2017-09-29 |
2019-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
|
|
GB201717578D0
(en)
|
2017-10-26 |
2017-12-13 |
Univ College Cardiff Consultants Ltd |
Novel T-cell receptor
|
|
CN112088008B
(zh)
|
2018-01-11 |
2024-01-02 |
浙江煦顼技术有限公司 |
修饰细胞的扩增及其用途
|
|
CA3095920A1
(en)
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
|
EP3806857A4
(en)
|
2018-06-14 |
2022-03-02 |
2seventy bio, Inc. |
CD79A CHIMERIC ANTIGEN RECEPTORS
|
|
JP2021527409A
(ja)
|
2018-06-14 |
2021-10-14 |
ブルーバード バイオ， インコーポレイテッド |
Ｃｄ７９ａキメラ抗原受容体
|
|
US20210393692A1
(en)
|
2018-11-13 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
US20240034768A1
(en)
*
|
2018-12-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
EP3714941A1
(en)
|
2019-03-27 |
2020-09-30 |
Medigene Immunotherapies GmbH |
Mage-a4 tcrs
|
|
KR20220004751A
(ko)
|
2019-05-04 |
2022-01-11 |
인히브릭스, 인크. |
CLEC12a 결합 폴리펩타이드 및 이의 용도
|
|
JP2022532868A
(ja)
|
2019-05-04 |
2022-07-20 |
インヒブルクス インコーポレイテッド |
Ｃｄ１２３結合性ポリペプチド及びその使用
|
|
CN114040927A
(zh)
|
2019-05-04 |
2022-02-11 |
印希比股份有限公司 |
结合cd33的多肽及其用途
|
|
KR20220031554A
(ko)
*
|
2019-05-08 |
2022-03-11 |
인히브릭스, 인크. |
Cd33 표적화 면역요법
|
|
US12421315B2
(en)
*
|
2019-05-08 |
2025-09-23 |
Regeneron Pharmaceuticals, Inc. |
CLL-1 targeted immunotherapies
|
|
US20220280567A1
(en)
|
2019-06-14 |
2022-09-08 |
2Seventy Bio, Inc. |
Compositions and methods for treating cancer
|
|
AU2020359530A1
(en)
*
|
2019-09-30 |
2022-05-19 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
AU2021244594A1
(en)
|
2020-03-27 |
2022-12-01 |
Regeneron Pharmaceuticals, Inc. |
T cell receptors
|
|
EP4136119A4
(en)
|
2020-04-17 |
2024-09-11 |
Regeneron Pharmaceuticals, Inc. |
MODIFIED CCR POLYPEPTIDES AND USES THEREOF
|
|
WO2021260696A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Ramot At Tel-Aviv University Ltd. |
Multi subunit protein modules, cells expressing same and uses thereof
|
|
US20230310604A1
(en)
|
2020-08-25 |
2023-10-05 |
2Seventy Bio, Inc. |
Bcma chimeric antigen receptors
|